Literature DB >> 9545344

Tissue plasminogen activator binding to the annexin II tail domain. Direct modulation by homocysteine.

K A Hajjar1, L Mauri, A T Jacovina, F Zhong, U A Mirza, J C Padovan, B T Chait.   

Abstract

Tissue plasminogen activator binds to endothelial cells via the calcium-regulated phospholipid-binding protein annexin II, an interaction that is inhibited by the prothrombotic amino acid homocysteine. We sought to identify the tissue plasminogen activator binding domain of annexin II and to determine the mechanism of its modulation by homocysteine. Tissue plasminogen activator binding to immobilized annexin II was inhibited by intact fluid phase annexin II but not by its "core" fragment (residues 25-339). Two overlapping "tail" peptides specifically blocked 65-75% of binding. Localization of the tissue plasminogen activator binding domain was confirmed upon specific inhibition by the hexapeptide LCKLSL (residues 7-12). Expressed C9G annexin II protein failed to support tissue plasminogen activator binding, while binding to C133G, C262G, and C335G was equivalent to that of wild type annexin II. Upon exposure to homocysteine, annexin II underwent a 135 +/- 4-Da increase in mass localizing specifically to Cys9 and a 60-66% loss in tissue plasminogen activator-binding capacity (I50 = 11 microM). Upon treatment of cultured endothelial cells with [35S]homocysteine, the dithiothreitol-sensitive label was recovered by immunoprecipitation with anti-annexin II IgG. These data provide a potential mechanism for the prothrombotic effect of homocysteine by demonstrating direct blockade of the tissue plasminogen activator binding domain of annexin II.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9545344     DOI: 10.1074/jbc.273.16.9987

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

1.  Incrimination of heterogeneous nuclear ribonucleoprotein E1 (hnRNP-E1) as a candidate sensor of physiological folate deficiency.

Authors:  Ying-Sheng Tang; Rehana A Khan; Yonghua Zhang; Suhong Xiao; Mu Wang; Deborah K Hansen; Hiremagalur N Jayaram; Aśok C Antony
Journal:  J Biol Chem       Date:  2011-09-19       Impact factor: 5.157

2.  Tissue Plasminogen Activator: Side Effects and Signaling.

Authors:  Ling Lin; Kebin Hu
Journal:  J Drug Des Res       Date:  2014-09-25

3.  Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation.

Authors:  Manel G Medina; Maria Dolores Ledesma; Jorge E Domínguez; Miguel Medina; Delia Zafra; Francesc Alameda; Carlos G Dotti; Pilar Navarro
Journal:  EMBO J       Date:  2005-04-21       Impact factor: 11.598

Review 4.  The endothelial cell annexin A2 system and vascular fibrinolysis.

Authors:  MaryAnn Dassah; Arun B Deora; Kaili He; Katherine A Hajjar
Journal:  Gen Physiol Biophys       Date:  2009       Impact factor: 1.512

Review 5.  The annexin A2 system and vascular homeostasis.

Authors:  Elle C Flood; Katherine A Hajjar
Journal:  Vascul Pharmacol       Date:  2011-03-29       Impact factor: 5.773

6.  Enhanced susceptibility to arterial thrombosis in a murine model of hyperhomocysteinemia.

Authors:  Sanjana Dayal; Katina M Wilson; Lorie Leo; Erland Arning; Teodoro Bottiglieri; Steven R Lentz
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

Review 7.  Molecular targeting of proteins by L-homocysteine: mechanistic implications for vascular disease.

Authors:  Alla V Glushchenko; Donald W Jacobsen
Journal:  Antioxid Redox Signal       Date:  2007-11       Impact factor: 8.401

Review 8.  Annexin A2: biology and relevance to the antiphospholipid syndrome.

Authors:  E Cockrell; R G Espinola; K R McCrae
Journal:  Lupus       Date:  2008-10       Impact factor: 2.911

Review 9.  Homocysteine, MTHFR gene polymorphisms, and cardio-cerebrovascular risk.

Authors:  Elisabetta Trabetti
Journal:  J Appl Genet       Date:  2008       Impact factor: 3.240

Review 10.  Annexin A2 system in human biology: cell surface and beyond.

Authors:  Min Luo; Katherine A Hajjar
Journal:  Semin Thromb Hemost       Date:  2013-03-12       Impact factor: 4.180

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.